DIM
BIO icon

DC Investments Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

DC Investments Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-692
Closed -$312K – 98
2020
Q2 		$312K Buy
+692
New +$305K 0.11% 189

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

DC Investments Management's BIO Position: Q3 2020 in Review

DC Investments Management sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2020, closing a stake of 692 shares — an estimated $312K sold.

DC Investments Management first reported a position in BIO in Q2 2020 and held it in 1 quarter. The position peaked at $312K in Q2 2020. 479 funds tracked by Wall St. Rank hold BIO as of Q3 2020.

  • DC Investments Management reported no remaining Bio-Rad Laboratories Class A position as of Q3 2020 after selling out during the quarter.
  • DC Investments Management sold 692 Bio-Rad Laboratories Class A shares in Q3 2020, an estimated $312K.
  • DC Investments Management first reported a position in Bio-Rad Laboratories Class A in Q2 2020 and held it in 1 quarter.
  • DC Investments Management's Bio-Rad Laboratories Class A position peaked at $312K in Q2 2020.
  • 479 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2020.

Based on DC Investments Management's 13F filing for Q3 2020, filed 4 Nov 2020.